Agents such as poly ADP-ribose polymerase (PARP) inhibitors, PI3K inhibitors, androgen receptor inhibitors, cyclin-dependent kinase (CDK) inhibitors, epidermal growth factor receptor (EGFR) signaling pathway inhibitors, fibroblast growth factor receptor (FGFR) inhibitors, and vascular endothelial growth factor receptor (VEGFR) inhibitors have demonstrated promising therapeutic effects in breast cancer management [61]. This evidence concerns the gene KDR and breast carcinoma.